000304494 001__ 304494
000304494 005__ 20250911114928.0
000304494 0247_ $$2doi$$a10.1007/s11060-025-05223-6
000304494 0247_ $$2pmid$$apmid:40931258
000304494 0247_ $$2ISSN$$a0167-594X
000304494 0247_ $$2ISSN$$a1573-7373
000304494 037__ $$aDKFZ-2025-01883
000304494 041__ $$aEnglish
000304494 082__ $$a610
000304494 1001_ $$00000-0002-2824-3720$$aRenovanz, Mirjam$$b0
000304494 245__ $$aPhysician-led versus questionnaire-based psychosocial screening in adults with high-grade glioma: a cluster-randomized controlled trial (GLIOPT).
000304494 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2025
000304494 3367_ $$2DRIVER$$aarticle
000304494 3367_ $$2DataCite$$aOutput Types/Journal article
000304494 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1757581939_26503
000304494 3367_ $$2BibTeX$$aARTICLE
000304494 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304494 3367_ $$00$$2EndNote$$aJournal Article
000304494 500__ $$aepub
000304494 520__ $$aPatients diagnosed with high-grade gliomas (HGG) often experience substantial psychosocial dis-tress. However, due to neurological and neurocognitive deficits its assessment remains challenging, and needs remain unmet. We compared a novel face-to-face assessment during doctor-patient conversations with questionnaire-based screening.In this multicenter, two-arm cluster-randomized study involving 13 centers patients in the interven-tion group (IG) were screened for distress via physician-patient conversations, while the control group (CG) completed the Distress Thermometer. Primary outcome was the proportion of patients with poor emotional functioning (measured with the EORTC Quality of Life Questionnaire) who received specialized psychosocial care (PC) within 3 months. Data were collected via patient and physician reports and medical records. Analysis employed mixed models logistic regression.In total, 763 patients were enrolled at baseline, and 506 completed the follow-up. The emotional functioning was poor in 302/506 (59.7%). The frequency of patients reporting PC utilization was comparable between groups (IG 93/168, 55.4% vs. CG 87/134, 64.9%, odds ratio (OR) =0.67, 95% confidence interval (CI)=0.40-1.11, p=0.115). Likewise, the provision of information about special-ized psycho-oncological care was similar (IG 112/168, 66.7% vs. CG 94/134, 70.1%, OR=0.95, 95%CI=0.39-2.29, p=0.904).Physician-led, face-to-face distress screening was not superior to questionnaire-based screening in facilitating psychosocial care referrals. Nonetheless, it represents a feasible and patient-centered alternative, particularly for patients with high-grade gliomas suffering from neurocognitive or func-tional deficits.
000304494 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000304494 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304494 650_7 $$2Other$$aAssessment
000304494 650_7 $$2Other$$aDistress
000304494 650_7 $$2Other$$aHigh-grade glioma
000304494 650_7 $$2Other$$aPrimary brain tumor patients
000304494 650_7 $$2Other$$aPsychosocial burden
000304494 650_7 $$2Other$$aPsychosocial care
000304494 650_7 $$2Other$$aScreening
000304494 650_7 $$2Other$$aSupportive care needs
000304494 7001_ $$aHippler, Melina$$b1
000304494 7001_ $$00000-0003-4384-7511$$aKuchen, Robert$$b2
000304494 7001_ $$aDoerner, Lorenz$$b3
000304494 7001_ $$00009-0003-6032-4760$$aRieger, David$$b4
000304494 7001_ $$00000-0002-4695-2483$$aSteinbach, Joachim P$$b5
000304494 7001_ $$00000-0002-1402-6290$$aRonellenfitsch, Michael W$$b6
000304494 7001_ $$00000-0001-8469-8204$$aVoss, Martin$$b7
000304494 7001_ $$00000-0002-0605-7791$$aKessler, Almuth F$$b8
000304494 7001_ $$00009-0002-0453-1135$$aNickl, Vera$$b9
000304494 7001_ $$00000-0001-5283-5753$$aMisch, Martin$$b10
000304494 7001_ $$00000-0002-2859-4395$$aOnken, Julia Sophie$$b11
000304494 7001_ $$00000-0003-2343-244X$$aRapp, Marion$$b12
000304494 7001_ $$00000-0003-1891-7389$$aNadji-Ohl, Minou$$b13
000304494 7001_ $$00000-0003-0017-9066$$aMehlitz, Marcus$$b14
000304494 7001_ $$00000-0002-1385-8255$$aMeixensberger, Jürgen$$b15
000304494 7001_ $$00000-0001-8396-7740$$aFehrenbach, Michael Karl$$b16
000304494 7001_ $$00000-0001-8457-0059$$aKeric, Naureen$$b17
000304494 7001_ $$00000-0003-3132-7543$$aRingel, Florian$$b18
000304494 7001_ $$00000-0002-3677-8258$$aCoburger, Jan$$b19
000304494 7001_ $$00000-0001-6463-0034$$aLucas, Carolin Weiß$$b20
000304494 7001_ $$aWehinger, Jens$$b21
000304494 7001_ $$00000-0002-3515-4427$$aSchmidt-Graf, Friederike$$b22
000304494 7001_ $$00000-0003-4123-4690$$aGempt, Jens$$b23
000304494 7001_ $$00000-0002-1627-9937$$aTatagiba, Marcos$$b24
000304494 7001_ $$aTabatabai, Ghazaleh$$b25
000304494 7001_ $$00000-0003-4476-0020$$aSchranz, Melanie$$b26
000304494 7001_ $$00000-0001-5784-7964$$aSinger, Susanne$$b27
000304494 773__ $$0PERI:(DE-600)2007293-4$$a10.1007/s11060-025-05223-6$$pnn$$tJournal of neuro-oncology$$vnn$$x0167-594X$$y2025
000304494 909CO $$ooai:inrepo02.dkfz.de:304494$$pVDB
000304494 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-4695-2483$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000304494 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-1402-6290$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000304494 9101_ $$0I:(DE-588b)2036810-0$$60000-0001-8469-8204$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000304494 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000304494 9141_ $$y2025
000304494 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-11$$wger
000304494 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-11$$wger
000304494 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-11$$wger
000304494 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURO-ONCOL : 2022$$d2024-12-11
000304494 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000304494 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000304494 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000304494 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000304494 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
000304494 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000304494 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000304494 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-11
000304494 9201_ $$0I:(DE-He78)FM01-20160331$$kFM01$$lDKTK Koordinierungsstelle Frankfurt$$x0
000304494 980__ $$ajournal
000304494 980__ $$aVDB
000304494 980__ $$aI:(DE-He78)FM01-20160331
000304494 980__ $$aUNRESTRICTED